Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients

Inclusion Criteria * Patients between 18 and 85 years old, inclusive * Patients with end stage renal disease (ESRD) who are currently undergoing hemodialysis treatment through an upper extremity fistula * Hemoglobin ≥8g/dL and platelet count ≥100,000/mm3 prior to Day 1 * Adequate liver function, defined as serum bilirubin ≤1.5 mg/dL; gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤2x upper limit of normal or international normalized ratio (INR) ≤ 1.5 prior to Day 0 or INR ≤ 2 if on anticoagulant therapy. * Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures * If female and of childbearing years, must have a negative serum pregnancy test at the screening visit (Visit 1). Both female patients of childbearing potential and male patients with childbearing potential partners must be willing to use contraception from the time of screening to completion of the study * Life expectancy of at least 1 year Exclusion Criteria * Known sensitivity to bevacizumab or prior treatment with any medication known to target VEGF * Current use of medications that are known to interact with the safety and efficacy of bevacizumab (most commonly: Antineoplastics (Anthracyclines), Belimumab, Bisphosphonate Derivatives, Clozapine, Dipyrone, Irinotecan, Sorafenib, and Sutent) * History or evidence of severe cardiac disease (N…